Middle East and Africa Hereditary Transthyretin Amyloidosis Market – Industry Trends and Forecast to 2030

Middle East and Africa Hereditary Transthyretin Amyloidosis Market Analysis and Size

The Middle East and Africa hereditary transthyretin amyloidosis market is expected to grow in the forecast year due to the rise in the number of market players and the availability of advanced technological diagnostic devices. The increasing development in the field of advanced techniques is further expected to boost market growth. However, difficulties such as the stringent regulations for the production and commercialization of treatment drugs and medical devices for diagnosis and surgery are expected to restrain market growth in the forecast period.

Data Bridge Market Research analyzes that, the Middle East and Africa hereditary transthyretin amyloidosis market is expected to reach the value of USD 65,985.45 thousand by 2030, at a CAGR of 3.1% during the forecast period. This market report also covers pricing analysis and technological advancements in depth.

Market Definition

The Middle East and Africa hereditary transthyretin amyloidosis market is a pharmaceutical and biotechnology market focused on the treatment and diagnosis of hATTR, a rare genetic disease characterized by the accumulation of abnormal transthyretin protein in tissues and organs, leading to various organ dysfunctions.

Hereditary transthyretin amyloidosis (hATTR) is a rare, inherited genetic disorder characterized by the accumulation of abnormal transthyretin protein (TTR) in various tissues and organs of the body. TTR is a protein primarily produced in the liver and is responsible for transporting thyroxine (a thyroid hormone) and retinol (vitamin A) in the bloodstream. In hATTR, a genetic mutation leads to the misfolding of TTR proteins, causing them to form amyloid fibrils that deposit in organs, disrupting their normal function. There are different forms of hATTR, including hereditary ATTR polyneuropathy (hATTR-PN) and hereditary ATTR cardiomyopathy (hATTR-CM). In hATTR-PN, the peripheral nerves are primarily affected, resulting in sensory, motor, and autonomic dysfunction. Patients may experience symptoms such as numbness, tingling, muscle weakness, and gastrointestinal problems.

Middle East and Africa Hereditary Transthyretin Amyloidosis Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Rising Prevalence of Hereditary Transthyretin Amyloidosis

Hereditary transthyretin amyloidosis (hATTR), also known as familial amyloid polyneuropathy (FAP), is a rare and inherited disorder characterized by the abnormal accumulation of amyloid fibrils in various organs and tissues of the body. Amyloid fibrils are misfolded proteins that clump together and can lead to organ dysfunction over time.

Transthyretin (TTR) is a protein primarily produced by the liver, and its normal function is to transport thyroxine (a thyroid hormone) and retinol (a form of vitamin A) in the blood. In hATTR, a genetic mutation causes the transthyretin protein to become unstable and more likely to misfold, leading to the formation of amyloid deposits.

The prevalence of hereditary transthyretin amyloidosis (hATTR) is on the rise due to various factors. Firstly, improved genetic testing methods have made it easier and more affordable to identify individuals at risk for hATTR, leading to earlier diagnoses and a better understanding of the disease's prevalence. Increased awareness of hATTR among medical professionals and the general public has resulted in more cases being recognized and diagnosed. Better reporting and data collection lead to a more accurate estimation of the prevalence of hATTR is emerging.

Lastly, the growing aging population has likely played a role in the increasing prevalence of hATTR. This condition typically has a later onset, and as the population ages, a larger number of individuals may develop symptoms of hATTR, leading to a rise in reported cases.

• Increasing Research and Clinical Trials for Hereditary Transthyretin Amyloidosis

There is an increase in research and clinical trials focused on hereditary transthyretin amyloidosis (hATTR) for the past few years. This surge in scientific interest can be attributed to several factors, including advancements in our understanding of the disease's genetic basis and pathophysiology. Researchers have identified various mutations in the transthyretin gene associated with hATTR, and this genetic knowledge has paved the way for targeted therapies.

One of the most promising therapeutic approaches for hATTR is the use of TTR stabilizers. These medications aim to stabilize the transthyretin protein, preventing it from misfolding and forming amyloid fibrils. In clinical trials, these drugs have shown promising results in slowing disease progression and improving patients' quality of life.

Another exciting avenue of research for hATTR is gene silencing therapy, specifically RNA interference (RNAi) and antisense oligonucleotides (ASOs). These treatments work by reducing the production of abnormal transthyretin protein, thereby reducing the amount of amyloid fibrils formed. Early clinical trials have shown encouraging results, with some gene silencing therapies demonstrating significant reductions in the levels of abnormal TTR protein in the blood.

In addition to these approaches, gene editing techniques, such as CRISPR-Cas9 are being explored for their potential in treating hATTR. CRISPR-Cas9 allows scientists to precisely edit the transthyretin gene, correcting or removing the disease-causing mutations. Although still in the early stages of development, gene editing holds promise for providing a more permanent and curative solution for hATTR.

Many countries have established patient registries to support research and clinical trials, that collect data on individuals with hATTR. These registries help researchers better understand the natural history of the disease, identify potential participants for clinical trials and track treatment outcomes.

Thus increasing research and clinical trials for hereditary transthyretin amyloidosis is expected to act as a driver for market growth.

Opportunity

Government Initiatives for Hereditary Transthyretin Amyloidosis Treatment

Increasing recognition by governmental bodies for the importance of addressing hereditary transthyretin amyloidosis (hATTR) and providing better support for affected individuals. These governmental initiatives are driven by the understanding that hATTR is a rare and severe genetic disease with a significant impact on patients' lives. The initiatives aim to improve awareness, research, patient care, and access to effective treatments for hATTR.

One crucial aspect of governmental initiatives is research funding. Governments have allocated funds to support scientific research on hATTR, both at the basic science level and for clinical studies. These funds encourage scientists and medical researchers to explore the disease's underlying mechanisms, identify potential therapeutic targets, and develop novel treatment approaches. Governments contribute to advancing knowledge about hATTR and potentially finding better ways to manage and treat the disease by providing financial support to research projects.

Thus, government initiatives for hereditary transthyretin amyloidosis treatment are expected to act as opportunities for market growth.

Restraints / Challenges

• High Cost Associated with Hereditary Transthyretin Amyloidosis Treatment

The high cost associated with hereditary transthyretin amyloidosis (hATTR) treatments can be a significant barrier for patients and healthcare systems.

Several factors contribute to the elevated expenses in developing and providing these therapies. Firstly, research and development (R&D) costs are a major driver of high treatment expenses. Developing new drugs, especially for rare diseases, such as hATTR, requires substantial investments in basic research, preclinical studies, and clinical trials. The cost of identifying potential drug targets, conducting animal studies, and moving through multiple phases of clinical trials can be substantial. Moreover, the risk of failure in the early stages of drug development means that companies must recoup the costs of both successful and unsuccessful ventures, further increasing the financial burden.

Thus, the high cost associated with hereditary transthyretin amyloidosis is expected to act as a restraint for market growth.

• Complexity in Diagnosing Hereditary Transthyretin Amyloidosis

The diagnosis of complex hereditary transthyretin amyloidosis (hATTR) can be a challenging and complex process due to the diverse clinical manifestations and the rarity of the disease. hATTR is a genetically heterogeneous disorder caused by mutations in the transthyretin (TTR) gene, leading to the accumulation of abnormal TTR protein as amyloid deposits in various organs, including the peripheral nerves, heart, and gastrointestinal system.

One of the critical steps in hATTR diagnosis is genetic testing to identify the specific mutation in the TTR gene. However, there are hundreds of known TTR gene mutations, and identifying the exact mutation can be challenging, requiring specialized genetic testing and expertise. Genetic testing is especially crucial in differentiating hATTR from other forms of amyloidosis, such as wild-type ATTR (ATTRwt) and AL amyloidosis, which may have overlapping clinical features.

Thus, complex hereditary transthyretin amyloidosis diagnosis is expected to act as a challenge for market growth.

Recent Development

• In June 2022, Alnylam Pharmaceuticals, Inc. received FDA authorization for AMVUTTRA (vutrisiran) for the treatment of Polyneuropathy of hereditary transthyretin-mediated amyloidosis.
• In April 2023, Canon Medical Systems Corporation announced that it had  begun clinical research by employing a next-generation X-ray CT system with photon counting computed tomography with the National Cancer Center Japan (NCC) . This will help the organization in developing its products category.
• In December 2022, a new technology AIR Recon DL was recently recognized in the “Best of What's New” awards by Popular Science magazine. It is a new technique developed by GE Healthcare for delivering high-quality images in a short amount of time. AIR Recon DL uses deep-learning technology to simultaneously improve MRI image quality and enable reduced scan time, improving the patient experience.

Middle East and Africa Hereditary Transthyretin Amyloidosis Market Scope

The Middle East and Africa hereditary transthyretin amyloidosis market is segmented into six notable segments, diagnosis and treatment, gene variation, gender, indication, end-user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 Diagnosis and Treatment

• Diagnosis
• Treatment

On the basis of diagnosis and treatment, the market is segmented into diagnosis and treatment.

 Gene Variation

• V122L
• T60A
• V30M
• Others

On the basis of gene variation, the market is segmented into V122L, T60A, V30M, and others.

Gender

• Male
• Female

On the basis of gender, the market is segmented into male and female.

Indication

• Cardiomyopathy (ATTR-CM)
• Polyneuropathy (ATTR-PN)
• Mixed Indications

On the basis of indications, the market is segmented into cardiomyopathy (ATTR-CM), polyneuropathy (ATTR-PN), and mixed indications.

End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Radiology Centers
• Academic and Research Institutes
• Ambulatory Surgical Centers
• Homecare

On the basis of end user, the market is segmented into hospitals and clinics, diagnostic laboratories, radiology centers, academic and research institutes, ambulatory surgical centers, and homecare.

Distribution Channel

• Direct Tender
• Third party Distributors
• Hospital Pharmacy
• Retail Pharmacy
• Others

On the basis of distribution channel, the market is segmented into direct tender, third party distributors, hospital pharmacy, retail pharmacy, and others.

Middle East and Africa Hereditary Transthyretin Amyloidosis Market Country Analysis/Insights

The Middle East and Africa hereditary transthyretin amyloidosis market is analyzed and market size insights and trends are provided by diagnosis and treatment, gene variation, gender, indication, end user, and distribution channel as referenced above.

The countries covered in Middle East and Africa hereditary transthyretin amyloidosis market are South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.

The South Africa is expected to dominate the market and be the fastest-growing due to the increase in disease awareness and education among both healthcare professionals and the public have likely contributed to the identification and management of conditions, such as hereditary transthyretin amyloidosis.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Hereditary Transthyretin Amyloidosis Market Share Analysis

The Middle East and Africa hereditary transthyretin amyloidosis market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major market players operating in the Middle East and Africa hereditary transthyretin amyloidosis market are Pfizer Inc, GE HealthCare, Siemens Healthcare GmbH, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS CORPORATION, Neusoft Corporation, NIHON KOHDEN CORPORATION., Shimadzu Corporation, Alnylam Pharmaceuticals, Inc., SCHILLER, Novo Nordisk A/S, FONAR Corp., and MinFound Medical Systems Co., among others.

SKU-70219